Lantern Pharma Inc reports results for the quarter ended in June - Earnings Summary

Lantern Pharma

08/08/2024 22:49

* Lantern Pharma Inc  LTRN.OQ  reported a quarterly adjusted
loss
of 46 cents​​ per share for the quarter ended in June, lower
than the same quarter last year, when the company reported EPS
of -44 cents.  The lone analyst forecast for the quarter was
for a loss of 55 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Lantern Pharma Inc's reported EPS for the quarter was a
loss
of 46 cents​.
    * The company reported a quarterly loss of $4.96 million.
    * Lantern Pharma Inc shares had fallen by 13.7% this
quarter and
lost 5.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 14.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Lantern Pharma
Inc is $18.00 
This summary was machine generated from LSEG data August 8 at
09:48 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.55          -0.46          Beat
 Mar. 31 2024      -0.43          -0.51          Missed
 Dec. 31 2023      -0.40          -0.39          Beat
 Sep. 30 2023      -0.45          -0.29          Beat